Arno Therapeutics Reports Second Quarter 2016 Financial And Business Update

FLEMINGTON, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended June 30, 2016 and provided an update on recent clinical developments for its lead compound, onapristone.

Back to news